Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

被引：0
|
作者：
Sorror, Mohamed L. [1 ]
Storer, Barry [1 ]
Sandmaier, Brenda M. [1 ]
Braunert, Leanthe [2 ]
Laport, Ginna G. [3 ]
Chauncey, Thomas [1 ,4 ]
Bredeson, Christopher [5 ]
Maziarz, Richard T. [6 ]
Pulsipher, Michael A. [7 ]
Agura, Edward [8 ]
Mans, Michael T. [9 ]
Vindelov, Lars [10 ]
Sahebi, Firoozeh [11 ]
McSweeney, Peter [12 ]
Bruno, Benedetto [13 ]
Langston, Amelia [14 ]
Storb, Rainer F. [1 ]
Maloney, David G. [1 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[2] Univ Leipzig, Leipzig, Germany
[3] Stanford Univ, Stanford, CA 94305 USA
[4] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[7] Univ Utah, Salt Lake City, UT USA
[8] Baylor Univ, Dallas, TX USA
[9] Rocky Mt Canc Ctr, Denver, CO USA
[10] Rigshosp, DK-2100 Copenhagen, Denmark
[11] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[12] Univ Colorado, Boulder, CO 80309 USA
[13] Univ Turin, Turin, Italy
[14] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：978 / 978
页数：1
相关论文
共 50 条
  • [41] Evaluation of Autologous and Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients With High-Risk Anaplastic Large Cell Lymphoma (ALCL)
    Smith, Natalie L.
    Summers, Corinne
    Gooley, Ted
    Shustov, Andrei
    Salit, Rachel
    Gardner, Rebecca
    Dahlberg, Ann
    Sorror, Mohamed L.
    Holmberg, Leona
    Sandmaier, Brenda M.
    Maloney, David
    Thakar, Monica S.
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 122 - 124
  • [42] Adding pen-transplant rituximab to nonmyeloablative (NMA) conditioning before allogeneic hematopoietic cell transplantation (allo-HCT) to improve disease-related outcomes in patients with chronic lymphocytic leukemia (CLL): Phase II clinical trial.
    Shadman, Mazyar
    Sorror, Mohamed L.
    Sandmaier, Brenda M.
    Storer, Barry
    Chauncey, Thomas R.
    Andersen, Niels Smedegaard
    Niederwieser, Dietger
    Bruno, Judith Shizurut Benedetto
    Pulsipher, Michael
    Maziarz, Richard T.
    Agura, Edward D.
    Hari, Parameswaran
    Langston, Amelia A.
    Maris, Michael B.
    McSweeney, Peter A.
    Storb, Rainer
    Maloney, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] The Effect of In Vivo T Cell Depletion with Alemtuzumab on Reduced-intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia
    Delgado, Julio
    Pillai, Srinivas
    Benjamin, Reuben
    Caballero, Dolores
    Martino, Rodrigo
    Nathwani, Amit
    Lovell, Richard
    Thomson, Kirsty
    Perez-Simon, Jose A.
    Sureda, Anna
    Kottaridis, Panagiotis
    Vazquez, Lourdes
    Peggs, Karl
    Sierra, Jorge
    Milligan, Donald
    Mackinnon, Stephen
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (11) : 1288 - 1297
  • [44] Past informs the future: outcomes post allogeneic stem cell transplantation in high risk chronic lymphocytic leukaemia (CLL)
    Bennett, Rory
    Frawley, Thomas
    Khot, Amit
    Thompson, Phillip
    Anderson, Mary Ann
    Ritchie, David
    LEUKEMIA & LYMPHOMA, 2023, 64 : S153 - S154
  • [45] Chronic lymphocytic Leukemia (CLL) Ibrutinib in the First Line: Standard for High-risk Patients
    Pickl, Susanne
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (1-2) : 76 - 76
  • [46] Ibrutinib in Patients (Pts) with Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) with Relapsed Disease Post Allogeneic Stem Cell Transplantation (alloSCT)
    Khouri, Issa F.
    Jabbour, Elias
    Saliba, Rima M.
    Ledesma, Celina
    Burger, Jan A.
    O'Brien, Susan
    Gulbis, Alison M.
    BLOOD, 2015, 126 (23)
  • [47] Flavopiridol is active in genetically high-risk, relapsed chronic lymphocytic leukemia (CLL): Analysis of 56 patients by cytogenetic abnormality.
    Lin, Thomas S.
    Heerema, Nyla A.
    Fischer, Beth
    Blum, Kristie A.
    Moran, Mollie E.
    McEldowney, Michelle B.
    Broering, Sara
    Lozanski, Gerard
    Colevas, Dimitrios
    Grever, Michael R.
    Byrd, John C.
    BLOOD, 2006, 108 (11) : 93A - 93A
  • [48] Nonmyeloablative unrelated donor hematopoietic cell transplantation (HCT) for patients (pts) with poor risk, relapsed or refractory multiple myeloma.
    Georges, GE
    Maris, MB
    Sandmaier, BM
    Shizuru, J
    Niederwieser, DW
    Agura, E
    Bruno, B
    McSweeney, PA
    Storb, RF
    Maloney, DG
    BLOOD, 2004, 104 (11) : 754A - 754A
  • [49] Serum miRNA Expression and Allogeneic Stem Cell Transplantation in Patients with B Chronic Lymphocytic Leukemia (CLL)
    Khouri, Issa F.
    Anfossi, Simone
    Saliba, Rima M.
    St John, Lisa S.
    Molldrem, Jeffrey J.
    Reuben, James M.
    BLOOD, 2014, 124 (21)
  • [50] Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with lymphoma and chronic lymphocytic leukemia (CLL) following targeted small molecules inhibitors (SMIs).
    Mukherjee, Akash
    Milton, Denai R.
    Jabbour, Elias
    Gulbis, Alison
    Kadia, Tapan M.
    Thompson, Philip A.
    Keating, Michael J.
    Jain, Nitin
    Ledesma, Celina
    Fayad, Luis
    Nastoupil, Loretta J.
    Burger, Jan Andreas
    Ferrajoli, Alessandra
    Estrov, Zeev
    Kantarjian, Hagop M.
    Champlin, Richard E.
    Khouri, Issa F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345